Stock analysts at Morgan Stanley initiated coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a note issued to investors on Tuesday. The brokerage set an “overweight” rating and a $25.00 price target on the stock. Morgan Stanley’s price target would suggest a potential upside of 50.15% from the company’s previous close.
Separately, JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $24.00 target price for the company.
Denali Therapeutics (NASDAQ DNLI) traded up $0.52 during trading hours on Tuesday, reaching $16.65. The company’s stock had a trading volume of 358,100 shares, compared to its average volume of 462,800. Denali Therapeutics has a 1 year low of $14.72 and a 1 year high of $22.95. The firm has a market capitalization of $1,450.00 and a PE ratio of -16.17.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/01/04/denali-therapeutics-dnli-now-covered-by-morgan-stanley.html.
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.